Is metformin a geroprotector? A peek into the current clinical and experimental data
Self archived versionfinal draft
MetadataShow full item record
CitationZajda, Agnieszka. Huttunen, Kristiina M. Sikora, Joanna. Podsiedlik, Maria. Markowicz-Piasecka, Magdalena. (2020). Is metformin a geroprotector? A peek into the current clinical and experimental data. Mechanisms of ageing and development, 191, 111350. 10.1016/j.mad.2020.111350.
Nowadays we observe a growing scientific interest and need to develop novel research approach that target ageing. Metformin, apart from its proven efectiveness as a glucose-lowering agent, was found to exert multidirectional effects because of its cardioprotective, anti-inflammatory and anti-cancer activity. Recently, metformin has become a subject of interest of many researchers as a promising drug with anti-ageing properties; however, its impact on clinical ageing features is still hypothetical. Nevertheless, results of cellular experiments and animal studies confirm that metformin has advantageous effects on ageing. Additionally, a number of clinical trials prove positive effects of metformin on the prevalence of age-related diseases (ARD), including cardiovascular disease or carcinoma. We have observed a significant advancement in human research since a few randomised clinical trials evaluating the impact of metformin on ageing were launched.
Here, we present an investigation on anti-ageing properties of metformin, and provide the explanation of mechanisms and pathways implicated in this function. We also analyse available clinical evidence on healthspan extension, all-cause mortality and ARD. Finally, we discuss currently conducted randiomized clinical trials which aim to explore metformin potential as an anti-ageing drug in humans.
Subjectsmetformin biguanides senescence geroprotector ageing
Link to the original itemhttp://dx.doi.org/0.1016/j.mad.2020.111350
- Terveystieteiden tiedekunta